stella
beta
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. — Stella
Recruiting
Back to Non-Small-Cell Lung Cancer trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Guangdong Provincial People's Hospital, Guangzhou, Guangdong
View full record on ClinicalTrials.gov